Omeprazol Teva (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Teva, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease, peptic ulcer disease, and ulcer prophylaxis in patients receiving non‑steroidal anti‑inflammatory drugs.

GNH USA supplies Omeprazol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Omeprazole, the proton pump inhibitor in Omeprazol Teva, is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal mucosal damage. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid production. - NSAID‑induced ulcer prophylaxis: reduces risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens aimed at eradicating H. pylori infection.

Adverse reactions may occur with any dose of Omeprazol Teva.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort or cramping in the stomach area. - Diarrhea: loose, watery stools. - Nausea: feeling of queasiness. - Flatulence: excess gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: signs of hepatic dysfunction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy with Omeprazol Teva, consider the following safety measures.

- Assess renal function: adjust use in patients with severe kidney impairment. - Use cautiously in hepatic impairment: monitor liver enzymes. - Monitor for drug interactions: especially with medications that require acidic environment for absorption. - Avoid abrupt discontinuation: taper dose to prevent rebound acid hypersecretion. - Use the lowest effective dose: limit duration to the shortest period needed for therapeutic effect. - Store at below 25°C: keep in the original pack, protect from moisture.

Omeprazol Teva can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: increased risk of serious cardiac arrhythmias. - Ketoconazole: markedly reduced absorption leading to therapeutic failure. - Atazanavir: decreased antiviral efficacy due to reduced gastric acidity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Phenytoin: possible reduction in seizure control, observe plasma levels. - Methotrexate: increased toxicity risk, especially at high doses.